hydroxyurea has been researched along with Cell Transformation, Neoplastic in 87 studies
Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aims of this study were (1) to detect involvement of N- and K-ras mutations in codons 12 and 13 in the pathogenesis of the chronic and blastic phases of PV and ET, (2) to study the occurrence of microsatellite instability (MSI) in chromosomes 5 and 7 during the chronic phase and blastic transformation of the disease, and (3) to examine the incidence of leukemia in patients treated with hydroxyurea (HU)." | 9.10 | Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. ( Loukopoulos, D; Madzourani, M; Mavrogianni, D; Meletis, J; Michali, E; Pangalis, G; Terpos, E; Vaiopoulos, G; Viniou, N; Yataganas, X, 2002) |
| "Criteria of response and definition of resistance and intolerance to hydroxyurea (HU) in polycythemia vera (PV) were proposed by the European LeukemiaNet (ELN)." | 7.78 | Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Ferrer-Marín, F; Gómez, M; Guillén, H; Hernández-Boluda, JC; Muiña, B; Pereira, A; Teruel, A; Vicente, V, 2012) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 7.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "From 1981 to 1995, we diagnosed, followed and treated at our institution fifty-eight cases of essential thrombocythemia (ET), using hydroxyurea (HU) as first-line therapy in these patients." | 7.69 | Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. ( Bordessoule, D; Brigaudeau, C; Desangles, F; Fermeaux, V; Liozon, E; Praloran, V; Trimoreau, F, 1997) |
| " The aims of this study were (1) to detect involvement of N- and K-ras mutations in codons 12 and 13 in the pathogenesis of the chronic and blastic phases of PV and ET, (2) to study the occurrence of microsatellite instability (MSI) in chromosomes 5 and 7 during the chronic phase and blastic transformation of the disease, and (3) to examine the incidence of leukemia in patients treated with hydroxyurea (HU)." | 5.10 | Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients. ( Loukopoulos, D; Madzourani, M; Mavrogianni, D; Meletis, J; Michali, E; Pangalis, G; Terpos, E; Vaiopoulos, G; Viniou, N; Yataganas, X, 2002) |
| "Criteria of response and definition of resistance and intolerance to hydroxyurea (HU) in polycythemia vera (PV) were proposed by the European LeukemiaNet (ELN)." | 3.78 | Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Ferrer-Marín, F; Gómez, M; Guillén, H; Hernández-Boluda, JC; Muiña, B; Pereira, A; Teruel, A; Vicente, V, 2012) |
| " We describe the case of a 62-year-old man who developed precursor T-cell (pre-T) ALL 18 months after the diagnosis of an unclassifiable chronic myeloproliferative syndrome (CMPD, U), which had been treated with hydroxyurea (HU) over 12 months." | 3.74 | A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia. ( Bacher, U; Haferlach, C; Haferlach, T; Harich, HD; Kern, W; Schnittger, S, 2007) |
| "In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%." | 3.69 | Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996) |
| "From 1981 to 1995, we diagnosed, followed and treated at our institution fifty-eight cases of essential thrombocythemia (ET), using hydroxyurea (HU) as first-line therapy in these patients." | 3.69 | Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. ( Bordessoule, D; Brigaudeau, C; Desangles, F; Fermeaux, V; Liozon, E; Praloran, V; Trimoreau, F, 1997) |
| "SIRs for acute myelogenous leukemia (AML) were high in ET patients." | 2.87 | Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. ( Achenbach, H; Besses, C; Birgegård, G; Folkvaljon, F; Garmo, H; Griesshammer, M; Gugliotta, L; Harrison, CN; Holmberg, L; Kiladjian, JJ; Wu, J, 2018) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "The patient who had trisomy 8 at the time of diagnosis underwent myeloid blastic transformation in 35 months." | 1.31 | Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases. ( Hirose, Y; Masaki, Y; Sugai, S, 2002) |
| "Hydroxyurea-treated primary B lymphocytes immortalized by EBV ceased to proliferate as episomes were lost." | 1.30 | Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. ( Belgaumi, A; Chodosh, J; Gan, YJ; Holder, VP; Sample, J; Sixbey, JW, 1998) |
| "The HEL cells, a human erythroleukemia cell line, express mainly the fetal globin gene and small amount of the embryonic (epsilon) globin gene, but not the adult (beta) globin gene." | 1.30 | [The role of hydroxyurea in globin gene expression and cell differentiation of human erythroleukemia cell line]. ( Gui, CY; Jiang, C; Qian, RL, 1997) |
| "Cytogenetic studies of chronic myelogenous leukemia (CML) have shown that the majority of hemopoietic cells originate from pluripotential stem cells affected in this disease." | 1.26 | Philadelphia-chromosome-positive pre-B-cell leukemia presenting as blast crisis of chronic myelogenous leukemia. ( Brattain, MG; Coleman, MS; Crist, WM; Sarrif, A; Vinson, PC; Vogler, LB, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 48 (55.17) | 18.7374 |
| 1990's | 8 (9.20) | 18.2507 |
| 2000's | 18 (20.69) | 29.6817 |
| 2010's | 13 (14.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, Y | 1 |
| Maule, J | 1 |
| Li, Y | 1 |
| Neff, J | 1 |
| McCall, CM | 1 |
| Hao, T | 1 |
| Yang, W | 1 |
| Rehder, C | 1 |
| Yang, LH | 1 |
| Wang, E | 1 |
| Hong, J | 1 |
| Lee, JH | 1 |
| Byun, JM | 1 |
| Lee, JY | 1 |
| Koh, Y | 1 |
| Shin, DY | 1 |
| Lee, JO | 1 |
| Hwang, SM | 1 |
| Choi, HS | 1 |
| Kim, I | 1 |
| Yoon, SS | 1 |
| Bang, SM | 1 |
| Janakiram, M | 1 |
| Verma, A | 1 |
| Wang, Y | 1 |
| Budhathoki, A | 1 |
| Suarez Londono, J | 1 |
| Murakhovskaya, I | 1 |
| Braunschweig, I | 1 |
| Minniti, CP | 1 |
| Birgegård, G | 1 |
| Folkvaljon, F | 1 |
| Garmo, H | 1 |
| Holmberg, L | 1 |
| Besses, C | 3 |
| Griesshammer, M | 1 |
| Gugliotta, L | 2 |
| Wu, J | 1 |
| Achenbach, H | 1 |
| Kiladjian, JJ | 1 |
| Harrison, CN | 1 |
| Marcellino, B | 1 |
| Hoffman, R | 1 |
| Mascarenhas, J | 1 |
| Cuthbert, D | 1 |
| Stein, BL | 1 |
| Bain, BJ | 1 |
| Garnett, C | 1 |
| Deplano, S | 1 |
| Naresh, K | 1 |
| Kanfer, E | 1 |
| Jeong, YT | 1 |
| Cermak, L | 1 |
| Guijarro, MV | 1 |
| Hernando, E | 1 |
| Pagano, M | 1 |
| Alvarez-Larrán, A | 2 |
| Cervantes, F | 2 |
| Björkholm, M | 1 |
| Hultcrantz, M | 1 |
| Derolf, ÅR | 1 |
| Goto, H | 1 |
| Hara, T | 1 |
| Tsurumi, H | 1 |
| Tanabashi, S | 1 |
| Moriwaki, H | 1 |
| Sandhu, G | 1 |
| Ranade, A | 1 |
| Siddiqi, S | 1 |
| Balderacchi, JL | 1 |
| Barbui, T | 4 |
| Finazzi, G | 2 |
| Pereira, A | 1 |
| Arellano-Rodrigo, E | 1 |
| Hernández-Boluda, JC | 1 |
| Ferrer-Marín, F | 1 |
| Angona, A | 1 |
| Gómez, M | 1 |
| Muiña, B | 1 |
| Guillén, H | 1 |
| Teruel, A | 1 |
| Bellosillo, B | 1 |
| Burgaleta, C | 1 |
| Vicente, V | 1 |
| Koren-Michowitz, M | 1 |
| Landman, J | 1 |
| Cohen, Y | 1 |
| Rahimi-Levene, N | 1 |
| Salomon, O | 1 |
| Michael, M | 1 |
| Amariglio, N | 1 |
| Nagler, A | 1 |
| Ellis, AK | 1 |
| Lee, DH | 1 |
| Barosi, G | 1 |
| Grossi, A | 1 |
| Liberato, LN | 1 |
| Marchetti, M | 1 |
| Mazzucconi, MG | 1 |
| Rodeghiero, F | 1 |
| Tura, S | 1 |
| Li, N | 1 |
| Sood, S | 1 |
| Wang, S | 1 |
| Fang, M | 1 |
| Wang, P | 1 |
| Sun, Z | 1 |
| Yang, CS | 1 |
| Chen, X | 1 |
| Swords, R | 1 |
| Quinn, J | 1 |
| Fay, M | 1 |
| O'Donnell, R | 1 |
| Goldman, J | 1 |
| Murphy, PT | 1 |
| Chim, CS | 1 |
| Ma, SK | 1 |
| Bilousova, G | 1 |
| Marusyk, A | 1 |
| Porter, CC | 1 |
| Cardiff, RD | 1 |
| DeGregori, J | 1 |
| Burkitt, MJ | 1 |
| Raafat, A | 1 |
| Gangat, N | 1 |
| Wolanskyj, AP | 1 |
| McClure, RF | 1 |
| Li, CY | 1 |
| Schwager, S | 1 |
| Wu, W | 1 |
| Tefferi, A | 2 |
| Bacher, U | 1 |
| Haferlach, T | 1 |
| Kern, W | 1 |
| Harich, HD | 1 |
| Schnittger, S | 1 |
| Haferlach, C | 1 |
| Rupniak, HT | 1 |
| Paul, D | 1 |
| Brewer, PP | 1 |
| Hellman, KB | 1 |
| Tagger, AY | 1 |
| Wright, JA | 1 |
| Kinzel, V | 1 |
| Loehrke, H | 1 |
| Goerttler, K | 1 |
| Fürstenberger, G | 1 |
| Marks, F | 1 |
| Solal-Celigny, P | 1 |
| Desaint, B | 1 |
| Herrera, A | 1 |
| Chastang, C | 1 |
| Amar, M | 1 |
| Vroclans, M | 1 |
| Brousse, N | 1 |
| Mancilla, F | 1 |
| Renoux, M | 1 |
| Bernard, JF | 1 |
| Kapp, LN | 1 |
| Painter, RB | 1 |
| Chłopkiewicz, B | 1 |
| Koziorowska, JH | 1 |
| Mullinger, AM | 1 |
| Collins, AR | 1 |
| Johnson, RT | 1 |
| Lotem, J | 1 |
| Sachs, L | 1 |
| Erard, F | 1 |
| Dean, A | 1 |
| Schechter, AN | 1 |
| Lewensohn, R | 1 |
| Ringborg, U | 1 |
| Gurley, LR | 1 |
| Jett, JH | 1 |
| Mironescu, SG | 1 |
| Epstein, SM | 1 |
| DiPaolo, JA | 1 |
| Nand, S | 1 |
| Stock, W | 1 |
| Godwin, J | 1 |
| Fisher, SG | 1 |
| Liozon, E | 1 |
| Brigaudeau, C | 1 |
| Trimoreau, F | 1 |
| Desangles, F | 1 |
| Fermeaux, V | 1 |
| Praloran, V | 1 |
| Bordessoule, D | 1 |
| Shammas, MA | 2 |
| Xia, SJ | 1 |
| Shmookler Reis, RJ | 2 |
| Chodosh, J | 1 |
| Holder, VP | 1 |
| Gan, YJ | 1 |
| Belgaumi, A | 1 |
| Sample, J | 1 |
| Sixbey, JW | 1 |
| Jiang, XR | 1 |
| Jimenez, G | 1 |
| Chang, E | 1 |
| Frolkis, M | 1 |
| Kusler, B | 1 |
| Sage, M | 1 |
| Beeche, M | 1 |
| Bodnar, AG | 1 |
| Wahl, GM | 1 |
| Tlsty, TD | 1 |
| Chiu, CP | 1 |
| Hirano, T | 1 |
| Shiraishi, K | 1 |
| Adachi, K | 1 |
| Miura, S | 1 |
| Watanabe, H | 1 |
| Utiyama, H | 1 |
| Solberg, LA | 1 |
| Silverstein, MN | 1 |
| Gui, CY | 1 |
| Jiang, C | 1 |
| Qian, RL | 1 |
| Krsnik, I | 1 |
| Ferro, T | 1 |
| García Suárez, J | 1 |
| Vázquez Mazariego, Y | 1 |
| Cabello, P | 1 |
| Batchu, RB | 1 |
| Wang, JY | 1 |
| Munshi, NC | 1 |
| Mavrogianni, D | 1 |
| Viniou, N | 1 |
| Michali, E | 1 |
| Terpos, E | 1 |
| Meletis, J | 1 |
| Vaiopoulos, G | 1 |
| Madzourani, M | 1 |
| Pangalis, G | 1 |
| Yataganas, X | 1 |
| Loukopoulos, D | 1 |
| Hirose, Y | 1 |
| Masaki, Y | 1 |
| Sugai, S | 1 |
| Kit, S | 1 |
| Dubbs, DR | 1 |
| Smith, CA | 1 |
| Hanawalt, PC | 1 |
| Rozengurt, E | 1 |
| Po, CC | 1 |
| Liberti, P | 1 |
| Fischer-Fantuzzi, L | 1 |
| Vesco, C | 1 |
| Morris, AG | 1 |
| Lavialle, C | 1 |
| Suarez, HG | 1 |
| Stevenet, J | 1 |
| Estrade, S | 1 |
| Cassingena, R | 1 |
| Cunningham, I | 1 |
| Gee, T | 1 |
| Dowling, M | 1 |
| Chaganti, R | 1 |
| Bailey, R | 1 |
| Hopfan, S | 1 |
| Bowden, L | 1 |
| Turnbull, A | 1 |
| Knapper, W | 1 |
| Clarkson, B | 1 |
| Vogler, LB | 1 |
| Crist, WM | 1 |
| Vinson, PC | 1 |
| Sarrif, A | 1 |
| Brattain, MG | 1 |
| Coleman, MS | 1 |
| Melzer, MS | 1 |
| Ikenaga, M | 1 |
| Kakunaga, T | 1 |
| Liebeskind, D | 1 |
| Bases, R | 1 |
| Elequin, F | 1 |
| Neubort, S | 1 |
| Leifer, R | 1 |
| Goldberg, R | 1 |
| Koenigsberg, M | 1 |
| Tsutsui, T | 1 |
| Barrett, JC | 1 |
| Ts'o, PO | 1 |
| Hittelman, WN | 1 |
| Rao, PN | 1 |
| Lovinger, GG | 1 |
| Gilden, RV | 1 |
| Hatanaka, M | 1 |
| Bradley, MO | 1 |
| Kohn, KW | 1 |
| Sharkey, NA | 1 |
| Ewig, RA | 1 |
| Maruyama, Y | 1 |
| Feola, J | 1 |
| Nahum, AM | 1 |
| Hoffmann, PR | 1 |
| Darnell, JE | 1 |
| Zeindl-Eberhart, E | 1 |
| Rabes, HM | 1 |
| Champlin, RE | 1 |
| Golde, DW | 1 |
| Cleaver, JE | 1 |
| Kuroki, T | 1 |
| Jones, PA | 1 |
| Taderera, JV | 1 |
| Hawtrey, AO | 2 |
| Parrington, JM | 1 |
| Delhanty, JD | 1 |
| Baden, HP | 1 |
| Noonan, KD | 1 |
| Renger, HC | 1 |
| Basilico, C | 1 |
| Burger, MM | 1 |
| Scheffler, IE | 1 |
| Buttin, G | 1 |
| Seemayer, NH | 1 |
| Defendi, V | 1 |
| Hampar, B | 1 |
| Derge, JG | 1 |
| Showalter, SD | 1 |
| Garfinkle, B | 1 |
| McAuslan, BR | 1 |
| Lin, SS | 1 |
| Munyon, W | 1 |
| Scott-Burden, T | 1 |
| Robertson, G | 1 |
| Mironescu, S | 1 |
| Love, R | 1 |
| Hynes, RO | 1 |
| Bye, JM | 1 |
| Lieberman, MW | 1 |
| Poirier, MC | 1 |
| Mason, JE | 1 |
| DeVita, VT | 1 |
| Canellos, GP | 1 |
| Stryckmans, PA | 1 |
| Prempree, T | 1 |
| Merz, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients.[NCT00202644] | Phase 4 | 150 participants (Actual) | Interventional | 2006-01-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Thrombohaemorrhagic events are a well-known complication of the underlying essential thrombocythemia (ET) and disease progression. Events such as arterial and venous thrombosis, serious haemorrhage (including gastrointestinal haemorrhage), and death from vascular causes have been reported in participants who received cytoreductive treatment. (NCT00202644)
Timeframe: From the signing of informed consent until the last study-related visit (Month 36)
| Intervention | participants (Number) |
|---|---|
| Anagrelide | 30 |
| Hydroxyurea | 16 |
A complete response was defined as a platelet count of less than (<) 400x10^9/Liter which was confirmed over 2 consecutive visits at least 28 days apart. (NCT00202644)
Timeframe: Baseline up to Month 36
| Intervention | percenatge of participants (Number) |
|---|---|
| Anagrelide | 58.9 |
| Hydroxyurea | 58.8 |
A partial response is defined as a platelet count of 400-600 x 10^9/Liter and a reduction in platelet count of at least 200 x 10^9/Liter from baseline which was confirmed over 2 consecutive visits at least 28 days apart. (NCT00202644)
Timeframe: Baseline up to Month 36
| Intervention | percentage of participants (Number) |
|---|---|
| Anagrelide | 21.9 |
| Hydroxyurea | 27.9 |
Platelet count was evaluated. (NCT00202644)
Timeframe: Month 6
| Intervention | 10^9 platelets per liter (Mean) |
|---|---|
| Anagrelide | 418.6 |
| Hydroxyurea | 396.0 |
Time in days from the date of the first dose of study medication to the date of the first visit at which response was classified. If a participant did not achieve response then they were censored at their last visit in the study (Month 36 or withdrawal). (NCT00202644)
Timeframe: Baseline up to Month 36
| Intervention | days (Median) |
|---|---|
| Anagrelide | 177.0 |
| Hydroxyurea | 123.0 |
Time in days from the date of the first dose of study medication to the date of the first visit at which response was classified. If a participant did not achieve response then they were censored at their last visit in the study (Month 36 or withdrawal). (NCT00202644)
Timeframe: Baseline up to Month 36
| Intervention | days (Median) |
|---|---|
| Anagrelide | 61.0 |
| Hydroxyurea | 47.0 |
The LVEF was measured by echocardiography and considered a sufficiently sensitive measure to evaluate any changes in cardiac function. (NCT00202644)
Timeframe: Baseline and Month 1, 2, 3, 6, 9, 12, 18, 24, 30 and 36
| Intervention | percentage of ejection fraction (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from baseline at Month 1 | Change from baseline at Month 2 | Change from baseline at Month 3 | Change from baseline at Month 6 | Change from baseline at Month 9 | Change from baseline at Month 12 | Change from baseline at Month 18 | Change from baseline at Month 24 | Change from baseline at Month 30 | Change from baseline at Month 36 | |
| Anagrelide | 66.4 | 0.5 | 1.2 | 0.1 | -0.5 | -0.8 | -0.8 | -2.0 | -1.8 | -1.8 | -1.7 |
| Hydroxyurea | 66.9 | -1.1 | 0 | -0.4 | -0.6 | -1.5 | -0.6 | -1.2 | -1.7 | -0.2 | -0.6 |
Platelet count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 3 and 36
| Intervention | 10^9 platelets per liter (Mean) | |
|---|---|---|
| Change from baseline at Month 3 | Change from baseline at Month 36 | |
| Anagrelide | 575.3 | 531.0 |
| Hydroxyurea | 462.2 | 462.8 |
Red blood cell count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 6, 12, 18, 24, 30 and 36
| Intervention | 10^12 cells per liter (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Change from baseline at Month 6 | Change from baseline at Month 12 | Change from baseline at Month 18 | Change from baseline at Month 24 | Change from baseline at Month 30 | Change from baseline at Month 36 | |
| Anagrelide | 4.757 | -0.227 | -0.246 | -0.225 | -0.299 | -0.295 | -0.366 |
| Hydroxyurea | 4.787 | -1.467 | -1.398 | -1.323 | -1.281 | -1.339 | -1.362 |
White blood cell count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 6, 12, 18, 24, 30 and 36
| Intervention | 10^9 cells per liter (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Change from baseline at Month 6 | Change from baseline at Month 12 | Change from baseline at Month 18 | Change from baseline at Month 24 | Change from baseline at Month 30 | Change from baseline at Month 36 | |
| Anagrelide | 9.13 | -0.38 | -1.00 | -1.18 | -1.24 | -1.00 | -1.63 |
| Hydroxyurea | 10.20 | -5.02 | -4.79 | -4.46 | -4.82 | -4.59 | -4.46 |
14 reviews available for hydroxyurea and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Therapy-associated leukemic transformation in myeloproliferative neoplasms - What do we know?
Topics: Cell Transformation, Neoplastic; Hematologic Neoplasms; Humans; Hydroxyurea; Myeloproliferative Diso | 2019 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Ja | 2014 |
Special issues in myeloproliferative neoplasms.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Child; Female; Hemorrhage; Humans; Hydroxyur | 2011 |
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Cell Transformation, Neoplastic; Child; Clinical Tria | 2004 |
Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders.
Topics: Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Myeloproliferative Disorders; Nitric | 2006 |
Evolving management of essential thrombocythaemia.
Topics: Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Thrombocythemia, Essential; Thrombos | 2007 |
DNA replication fork movement rates in mammalian cells.
Topics: Animals; Autoradiography; Bloom Syndrome; Cell Line; Cell Transformation, Neoplastic; Centrifugation | 1982 |
A clinical update in polycythemia vera and essential thrombocythemia.
Topics: Age Factors; Carcinogens; Cell Transformation, Neoplastic; Chronic Disease; Enzyme Inhibitors; Femal | 2000 |
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol | 2001 |
Critique of "carcinogen-induced repair DNA synthesis".
Topics: Acetoxyacetylaminofluorene; Animals; Bromodeoxyuridine; Carcinogens; Cell Nucleus; Cell Transformati | 1979 |
Chronic myelogenous leukemia: recent advances.
Topics: Bone Marrow Transplantation; Busulfan; Cell Transformation, Neoplastic; Chromosomes, Human, 21-22 an | 1985 |
[Chemical carcinogenesis in vitro. 2].
Topics: Animals; Carcinogens; Cell Transformation, Neoplastic; Culture Techniques; Dactinomycin; DNA; Genes; | 1970 |
Current concepts in chronic myelogenous leukemia.
Topics: Alkaline Phosphatase; Blood; Bone Marrow Cells; Bone Marrow Examination; Busulfan; Cell Division; Ce | 1974 |
2 trials available for hydroxyurea and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukem | 2018 |
Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chromosomes, Human, Pai | 2002 |
71 other studies available for hydroxyurea and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Sequential development of human herpes virus 8-positive diffuse large B-cell lymphoma and chronic myelomonocytic leukemia in a 59 year old female patient with hemoglobin SC disease.
Topics: Antisickling Agents; Cell Transformation, Neoplastic; Disease Progression; Fatal Outcome; Female; He | 2019 |
Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Child; Disease Progress | 2019 |
Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Antineoplastic Agents; Cell Transformation, Neoplastic; F | 2018 |
Does hydroxycarbamide therapy really induce leukemic transformation in patients with essential thrombocythemia?
Topics: Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Thrombocythemia, Essentia | 2019 |
Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
Topics: Aged; Amino Acid Substitution; Antineoplastic Agents; Aspirin; Bone Marrow; Cell Lineage; Cell Trans | 2013 |
FBH1 protects melanocytes from transformation and is deregulated in melanomas.
Topics: Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; DNA Breaks, Double-Stranded; DNA He | 2013 |
Chronic neutrophilic leukemia with congenital Robertsonian translocation successfully treated with allogeneic bone marrow transplantation in a young man.
Topics: Bone Marrow Transplantation; Cell Transformation, Neoplastic; Chromosome Disorders; Chromosomes, Hum | 2009 |
Essential thrombocythemia transforming into acute biphenotypic leukemia in a patient on hydroxyurea monotherapy.
Topics: Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukemia, | 2009 |
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Drug Resistance; Drug T | 2012 |
JAK2V617F allele burden is associated with transformation to myelofibrosis.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Cell Transformation, Neoplastic; Female; Humans; Hydroxyure | 2012 |
Tumor lysis syndrome induced by hydroxyurea therapy for leukemic transformation of polycythemia vera.
Topics: Aged; Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Male; Polycythemia Vera; Tumor | 2002 |
Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Carcinogen | 2005 |
CML clonal evolution with resistance to single agent imatinib therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Transformation, Neoplastic; Clone C | 2005 |
Der(8)t(1;8) in myeloblastic transformation of ET with hydroxyurea as the sole prior treatment.
Topics: Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Hu | 2005 |
Impaired DNA replication within progenitor cell pools promotes leukemogenesis.
Topics: Animals; Cell Transformation, Neoplastic; Cells, Cultured; DNA; DNA Replication; E2F1 Transcription | 2005 |
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Transformation, N | 2007 |
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
Topics: Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Banding; Chromosome Painting; Di | 2007 |
Selective killing of transformed cells by exploitation of their defective cell cycle control by polyamines.
Topics: Animals; Cell Cycle; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Drug Resistance; Gua | 1980 |
Induction of endogenous murine type C virus by ultraviolet-irradiated herpes simplex virus: effect of metabolic inhibitors.
Topics: Animals; Cell Line; Cell Transformation, Neoplastic; Cell Transformation, Viral; Dactinomycin; DNA, | 1980 |
A comparison of ribonucleotide reductase activities in normal human fibroblast strains with their transformed counterparts.
Topics: Cell Division; Cell Line; Cell Transformation, Neoplastic; Fibroblasts; Humans; Hydroxyurea; Ribonuc | 1984 |
Suppression of the first stage of phorbol 12-tetradecanoate 13-acetate-effected tumor promotion in mouse skin by nontoxic inhibition of DNA synthesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Cell Transformation, Neoplastic; DNA Replication; Female; | 1984 |
Chronic myelomonocytic leukemia according to FAB classification: analysis of 35 cases.
Topics: Aged; Bone Marrow; Cell Transformation, Neoplastic; Cytarabine; Female; Humans; Hydroxyurea; Leukemi | 1984 |
Transforming activities of methotrexate, hydroxyurea and 5-fluorouracil in different cell systems.
Topics: Animals; Cell Line; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Do | 1983 |
Cell growth state determines susceptibility of repair DNA synthesis to inhibition by hydroxyurea and 1-beta-D-arabinofuranosylcytosine.
Topics: Animals; Cell Cycle; Cell Line; Cell Transformation, Neoplastic; Cricetinae; Cricetulus; Cytarabine; | 1983 |
Potential pre-screening for therapeutic agents that induce differentiation in human myeloid leukemia cells.
Topics: Antineoplastic Agents; Bromodeoxyuridine; Cell Line; Cell Transformation, Neoplastic; Complement C3; | 1980 |
Inhibitors of cell division reversibly modify hemoglobin concentration in human erythroleukemia K562 cells.
Topics: Cell Transformation, Neoplastic; Culture Media; Glutamine; Hemin; Hemoglobins; Humans; Hydroxyurea; | 1981 |
DNA-repair synthesis in blast cells from patients with acute myeloblastic leukaemia.
Topics: Alkylating Agents; Autoradiography; Bone Marrow; Cell Transformation, Neoplastic; DNA; DNA Repair; H | 1982 |
Cell cycle kinetics of Chinese hamster (CHO) cells treated with the iron-chelating agent picolinic acid.
Topics: Animals; Autoradiography; Cell Line; Cell Transformation, Neoplastic; Cricetinae; Cytological Techni | 1981 |
Relationship between morphological transformation and [3H]thymidine incorporation stimulated by a chemical carcinogen in postconfluent cultures of hamster embryo cells.
Topics: Animals; Autoradiography; Caffeine; Carcinogens; Cell Survival; Cell Transformation, Neoplastic; Cel | 1980 |
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic; | 1996 |
Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature.
Topics: Aged; Antisickling Agents; Cell Transformation, Neoplastic; Chromosome Aberrations; Female; Humans; | 1997 |
Induction of duplication reversion in human fibroblasts, by wild-type and mutated SV40 T antigen, covaries with the ability to induce host DNA synthesis.
Topics: Antigens, Polyomavirus Transforming; Aphidicolin; Cell Line; Cell Transformation, Neoplastic; DNA; D | 1997 |
Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype.
Topics: Animals; Burkitt Lymphoma; Cell Division; Cell Line; Cell Transformation, Neoplastic; Cell Transform | 1998 |
Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype.
Topics: Aspartic Acid; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplastic; Cyclin-Dependent | 1999 |
Co-localization of mitochondrial and double minute DNA in the nuclei of HL-60 cells but not normal cells.
Topics: Cell Cycle; Cell Nucleus; Cell Transformation, Neoplastic; Colonic Neoplasms; DNA Damage; DNA, Mitoc | 1999 |
[The role of hydroxyurea in globin gene expression and cell differentiation of human erythroleukemia cell line].
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; DNA-Binding Proteins; Erythroid-Specific DNA | 1997 |
Translocation t(4; 6)(q21; q27) in a case of primary thrombocythaemia in transformation.
Topics: Aged; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 6; Fatal | 2001 |
Expression of AAV Rep proteins in SV40-transformed and untransformed cells: reciprocal interaction with host DNA synthesis.
Topics: Antigens, Viral, Tumor; Aphidicolin; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplas | 2001 |
Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Busulfan; Cell Transformation, Neoplastic; Chromosomes, | 2002 |
Regulation of herpesvirus thymidine kinase activity in LM(TK) cells transformed by ultraviolet light-irradiated herpes simplex virus.
Topics: Cell Line; Cell Transformation, Neoplastic; Clone Cells; Cycloheximide; Cytarabine; Dactinomycin; De | 1977 |
Repair replication in human cells. Simplified determination utilizing hydroxyurea.
Topics: Bromodeoxyuridine; Cell Line; Cell Transformation, Neoplastic; Centrifugation, Density Gradient; DNA | 1976 |
Selective cytotoxicity for transformed 3T3 cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Bucladesine; Cell Division; Cell Line; Cell Survival; Cell Tran | 1976 |
Kinetics of DNA and histone messenger RNA synthesis in CV-1 monkey kidney cells infected with simian virus 40.
Topics: Cell Division; Cell Line; Cell Transformation, Neoplastic; DNA Replication; DNA, Viral; Histones; Hy | 1976 |
Simian virus 40-Chinese hamster kidney cell interaction. III. Characteristics of chemical induction in a clone of virogenic transformed cells.
Topics: Animals; Bucladesine; Caffeine; Cell Line; Cell Transformation, Neoplastic; Clone Cells; Cricetinae; | 1977 |
Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).
Topics: Adolescent; Adult; Asparaginase; Cell Transformation, Neoplastic; Chromosomes, Human, 21-22 and Y; C | 1979 |
Philadelphia-chromosome-positive pre-B-cell leukemia presenting as blast crisis of chronic myelogenous leukemia.
Topics: B-Lymphocytes; Cell Transformation, Neoplastic; Child; Chromosomes, Human, 21-22 and Y; Humans; Hydr | 1979 |
Excision of 4-nitroquinoline 1-oxide damage and transformed in mouse cells.
Topics: 4-Nitroquinoline-1-oxide; Adenine; Cell Transformation, Neoplastic; Cells, Cultured; DNA Repair; DNA | 1977 |
Diagnostic ultrasound: effects on the DNA and growth patterns of animal cells.
Topics: Animals; Cell Division; Cell Line; Cell Transformation, Neoplastic; Cells, Cultured; Chromatids; DNA | 1979 |
Morphological transformation, DNA damage, and chromosomal aberrations induced by a direct DNA perturbation of synchronized Syrian hamster embryo cells.
Topics: Animals; Bromodeoxyuridine; Cell Cycle; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultu | 1979 |
Mapping G1 phase by the structural morphology of the prematurely condensed chromosomes.
Topics: Cell Cycle; Cell Fusion; Cell Line; Cell Transformation, Neoplastic; Chromosomes; Cycloheximide; Dac | 1978 |
Effects of hydroxyurea on murine type C virus-specific DNA synthesis in newly infected cells.
Topics: Cell Transformation, Neoplastic; DNA, Viral; Hydroxyurea; Moloney murine leukemia virus; Nucleic Aci | 1978 |
Differential cytotoxicity between transformed and normal human cells with combinations of aminonucleoside and hydroxyurea.
Topics: Cell Division; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Hydroxyurea; Puromyc | 1977 |
Changes in cell age cohort composition of tumors and normal tissues by radiation and chemotherapy.
Topics: Animals; Cell Survival; Cell Transformation, Neoplastic; Fluorouracil; Hydroxyurea; Mice; Splenic Ne | 1976 |
Overview of chemotherapy of cancer of the larynx.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Cell Transf | 1975 |
Differential accumulation of virus-specific RNA during the cell cycle of adenovirus-transformed rat embyro cells.
Topics: Adenoviridae; Animals; Cell Division; Cell Nucleus; Cell Transformation, Neoplastic; Cells, Cultured | 1975 |
Variant protein patterns in hepatomas and transformed liver cell lines as determined by high resolution two-dimensional gel electrophoresis (2DE).
Topics: Animals; Cell Line; Cell Transformation, Neoplastic; Cells, Cultured; Diethylnitrosamine; Electropho | 1992 |
Excision repair in xeroderma pigmentosum group C cells is regulated differently in transformed cells and primary fibroblasts.
Topics: Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; DNA Repair; DNA Replic | 1988 |
Transformation of hamster cells in vitro by 1- -D arabinofuranosylcytosine, 5-fluorodeoxyuridine and hydroxyurea.
Topics: Animals; Cell Transformation, Neoplastic; Cricetinae; Culture Techniques; Cytarabine; Cytosine Nucle | 1972 |
Unscheduled DNA synthesis, u.v.-induced chromosome aberrations and SV 40 transformation in cultured cells from xeroderma pigmentosum.
Topics: Adult; Autoradiography; Cell Transformation, Neoplastic; Cells, Cultured; Child; Chromosome Aberrati | 1971 |
Surface changes in temperature-sensitive Simian virus 40-transformed cells.
Topics: Agglutination; Animals; Binding Sites; Cell Transformation, Neoplastic; Cells, Cultured; Concanavali | 1973 |
Conditionally lethal mutations in Chinese hamster cells. I. Isolation of a temperature-sensitive line and its investigation by cell cycle studies.
Topics: Animals; Cell Adhesion; Cell Count; Cell Division; Cell Line; Cell Survival; Cell Transformation, Ne | 1973 |
Analysis of minimal functions of simian virus 40. 3. Evidence for "host cell repair" of oncogenicity and infectivity of UV-irradiated simian virus 40.
Topics: Animals; Autoradiography; Caffeine; Cell Line; Cell Transformation, Neoplastic; Cells, Cultured; Cri | 1974 |
Enhanced activation of the repressed Epstein-Barr viral genome by inhibitors of DNA synthesis.
Topics: Burkitt Lymphoma; Cell Line; Cell Transformation, Neoplastic; Cytarabine; DNA; Genotype; Herpesvirus | 1974 |
Regulation of herpes simplex virus-induced thymidine kinase.
Topics: Animals; Avian Sarcoma Viruses; Cell Line; Cell Transformation, Neoplastic; Cycloheximide; Cytarabin | 1974 |
Expression of the viral thymidine kinase gene in herpes simplex virus-transformed L cells.
Topics: Animals; Cell Division; Cell Fractionation; Cell Nucleus; Cell Transformation, Neoplastic; Cytoplasm | 1974 |
Inhibition of glycoprotein and glycolipid synthesis in hamster embryo cells by cytosine arabinoside and hydroxyurea.
Topics: Animals; Carbon Radioisotopes; Cell Membrane; Cell Transformation, Neoplastic; Cells, Cultured; Cric | 1974 |
DNA synthesis and transformation induced in density-inhibited cultures of hamster embryo cells by the carcinogen benzo(alpha)pyrene.
Topics: Animals; Autoradiography; Benzopyrenes; Carcinogens; Cell Division; Cell Line; Cell Transformation, | 1974 |
Density and cell cycle dependence of cell surface proteins in hamster fibroblasts.
Topics: Animals; Blood; Carbon Radioisotopes; Cell Count; Cell Division; Cell Line; Cell Membrane; Cell Tran | 1974 |
Intragenomal distribution of DNA repair synthesis: repair in satellite and mainband DNA in cultured mouse cells.
Topics: Animals; Bromodeoxyuridine; Cell Transformation, Neoplastic; Cells, Cultured; Centrifugation, Densit | 1974 |
Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance.
Topics: Anemia; Azauridine; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Busulfan; Cell Trans | 1974 |
Does hydroxyurea inhibit chromosome repair in cultured human lymphocytes?
Topics: Cell Transformation, Neoplastic; Chromosome Aberrations; Culture Techniques; Humans; Hydroxyurea; Ly | 1969 |